Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 open-label age de-escalation trial of RH5.1 + R78C malaria vaccine with Matrix-M in Tanzanian adults and infants
PACTR202407803870883Phase 1Not yet recruiting
- Sponsor
- Ifakara Health Institute
- Start
- Jul 2024
- Modality
- Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of RH5.1, R78C and Matrix M in malaria (2 arms), sponsored by Ifakara Health Institute. Primary endpoint: Safety and tolerability of RH5.1 and R78C with Matrix-M. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
RH5.1R78CMatrix M
03
Conditions
malaria
Beyond the preview
Go deeper on PACTR202407803870883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202407803870883.